Home » Stocks » Anchiano Therapeutics

Anchiano Therapeutics Ltd. (ANCN)

Stock Price: $1.18 USD 0.05 (4.42%)
Updated Oct 27, 2020 4:00 PM EDT - Market closed
After-hours: $1.17 -0.01 (-0.85%) Oct 27, 5:13 PM

Stock Price Chart

Key Info

Market Cap 8.76M
Revenue (ttm) n/a
Net Income (ttm) -13.88M
Shares Out 7.42M
EPS (ttm) -2.67
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 27, 2020
Last Price $1.18
Previous Close $1.13
Change ($) 0.05
Change (%) 4.42%
Day's Open 1.14
Day's Range 1.14 - 1.20
Day's Volume 145,525
52-Week Range 0.51 - 2.51

More Stats

Market Cap 8.76M
Enterprise Value 207,447
Earnings Date (est) Nov 13, 2020
Ex-Dividend Date n/a
Shares Outstanding 7.42M
Float n/a
EPS (basic) -1.65
EPS (diluted) -2.67
FCF / Share -2.50
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 22,463
Short Ratio 0.41
Short % of Float n/a
Beta n/a
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 0.99
Revenue n/a
Operating Income -20.05M
Net Income -13.88M
Free Cash Flow -18.56M
Net Cash 8.55M
Net Cash / Share 1.15
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -48.52%
ROE -119.78%
ROIC 605.60%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (1)

Buy 0
Overweight 0
Hold 1
Underweight 0
Sell 0

Analyst Consensus: Hold

Price Target

Current: $1.18
Target: 1.00
*Average 12-month price target from 1 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Operating Income-22.90-13.04-9.39-4.64
Net Income-27.12-13.80-9.81-4.74
Shares Outstanding34.4512.6332.86-
Earnings Per Share-3.95-5.45-5.45-4.35
Operating Cash Flow-16.46-14.22-8.52-3.73
Capital Expenditures-0.10-0.21-0.03-0.08
Free Cash Flow-16.55-14.44-8.55-3.81
Cash & Equivalents17.587.521.454.56
Total Debt1.12---
Net Cash / Debt16.467.521.454.56
Book Value14.919.81-0.613.30
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Anchiano Therapeutics Ltd.
Country Israel
Employees 16
CEO Neil Cohen

Stock Information

Ticker Symbol ANCN
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: ANCN
IPO Date February 12, 2019


Anchiano Therapeutics Ltd, a clinical-stage biotechnology company, develops gene therapies to treat early-stage bladder cancer. It is primarily developing Inodiftagene that is in various clinical trials for the treatment of non-muscle-invasive bladder cancer. The company was formerly known as BioCancell Ltd. and changed its name Anchiano Therapeutics Ltd in July 2018. The company was founded in 2004 and is headquartered in Cambridge, Massachusetts.